Several aspects of medication reviews should be reviewed, including the cap on services, says PSA president Joe Demarte.
His comments followed the publication of a landmark study on the impact of medication reviews in Australia, which highlights the benefits of such services and finds they are valuable in identifying medication-related problems, improving medication adherence, reducing hospitalisations and minimising the use of potentially inappropriate medications.
The study, undertaken by Australian researchers and published in the internationally reputable Research in Social and Administrative Pharmacy journal, concluded that the available evidence suggests clinical medication reviews are beneficial in improving quality use of medications and consumer health outcomes.
The PSA welcomed the study. Demarte says the study provides important evidence underpinning the value of medication reviews.
“This review is landmark in that it provides an overview of the research to date and describes the clinical, humanistic, economic and qualitative benefits of medication reviews,” he says.
“It shows that medication reviews are evidenced-based and beneficial to the public and the health system.
“But it also identified opportunities for improvement – for example there are underserved populations who would benefit from the service, including post hospital discharge patients, indigenous and culturally and linguistically diverse people, and younger patients with chronic diseases.”
Demarte says the research findings provide a good opportunity to review the current administrative MMR changes imposed in the 5CPA.
“Namely we should review the cap on services, time interval between CMRs, and restriction of services to the patient’s place of residence,” Demarte says.
“With proven value, the PSA will certainly be strongly advocating that in the 6CPA, patients who would benefit from a medication review should be able to access one.”